Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study

Mangum, Ross; Reuther, Jacquelyn; Baksi, Koel Sen; Gandhi, Ilavarasi; Zabriskie, Ryan C.; Recinos, Alva; Raesz-Martinez, Robin; Lin, Frank; Potter, Samara L; Sher, Andrew; Kralik, Stephen F.; Mohila, Carrie A.; Chintagumpala, Murali; Hu, Jianhong; Gibbs, Richard A.; Fisher, Kevin E.; Bernini, Juan Carlos; Gill, Jonathan; Griffin, Timothy C.; Tomlinson, Gail E.; Vallance, Kelly; Plon, Sharon E.; Roy, Angshumoy; Parsons, D. Williams

doi:10.1080/08880018.2023.2228837

Cited by 2 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, cerebrospinal fluid is being studied as an alternative reservoir for detecting somatic mutations in ctDNA released from CNS tumors in an effort to bypass the blood brain barrier that complicates plasma ctDNA detection in these patients. 48,[58][59][60][61][62][63][64][65] The "omics"-based technologies listed in Table 2 have been utilized in numerous other disease-specific genomic analyses performed in the last several years. Such analysis can be utilized for a wide variety of purposes.…”

Section: Clinical Applications Of Genomic-based Technologiesmentioning

confidence: 99%

“…Furthermore, other biospecimens are also being investigated as alternative sources of tumor-specific genetic material. For example, cerebrospinal fluid is being studied as an alternative reservoir for detecting somatic mutations in ctDNA released from CNS tumors in an effort to bypass the blood brain barrier that complicates plasma ctDNA detection in these patients 48,58–65 …”

Section: Clinical Applications Of Genomic-based Technologiesmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advancements and Innovations in Pediatric Precision Oncology

Mangum,

Lin,

Parsons

2024

Journal of Pediatric Hematology/Oncology

Self Cite

View full text Add to dashboard Cite

Precision oncology incorporates comprehensive genomic profiling into the individualized clinical care of pediatric cancer patients. In recent years, comprehensive pan-cancer analyses have led to the successful implementation of genomics-based pediatric trials and accelerated approval of novel targeted agents. In addition, disease-specific studies have resulted in molecular subclassification of myriad cancer types with subsequent tailoring of treatment intensity based on the patient’s prognostic factors. This review discusses the progress of the field and highlights developments that are leading to more personalized cancer care and improved patient outcomes. Increased understanding of the evolution of precision oncology over recent decades emphasizes the tremendous impact of improved genomic applications. New technologies and improved diagnostic modalities offer further promise for future advancements within the field.

show abstract

Section: Clinical Applications Of Genomic-based Technologiesmentioning

confidence: 99%

Section: Clinical Applications Of Genomic-based Technologiesmentioning

confidence: 99%

Recent Advancements and Innovations in Pediatric Precision Oncology

Mangum,

Lin,

Parsons

2024

Journal of Pediatric Hematology/Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Incidental brain tumor findings in children: prevalence, natural history, management, controversies, challenges, and dilemmas

Soleman,

Constantini,

Roth

2024

Childs Nerv Syst

View full text Add to dashboard Cite

Incidental brain tumor findings in children involve the unexpected discovery of brain lesions during imaging for unrelated reasons. These findings differ significantly from those in adults, requiring a focus on pediatric-specific approaches in neurosurgery, neuroimaging, and neuro-oncology. Understanding the prevalence, progression, and management of these incidentalomas is crucial for informed decision-making, balancing patient welfare with the risks and benefits of intervention. Incidental brain tumors are observed in about 0.04–5.7% of cases, with most suspected low-grade lesions in children showing a benign course, though up to 3% may undergo malignant transformation. Treatment decisions are influenced by factors such as patient age, tumor characteristics, and family anxiety, with conservative management through surveillance often preferred. However, upfront surgery may be considered in cases with low surgical risk. Initial follow-up typically involves a comprehensive MRI after three months, with subsequent scans spaced out if the lesion remains stable. Changes in imaging or symptoms during follow-up could indicate malignant transformation, prompting consideration of surgery or biopsy. Several challenges and controversies persist, including the role of upfront biopsy for molecular profiling, the use of advanced imaging techniques like PET-CT and magnetic resonance spectroscopy, and the implications of the child’s age at diagnosis. These issues highlight the need for further research to guide management and improve outcomes in pediatric patients with incidental brain tumor findings.

show abstract

Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study

Cited by 2 publications

References 53 publications

Recent Advancements and Innovations in Pediatric Precision Oncology

Recent Advancements and Innovations in Pediatric Precision Oncology

Incidental brain tumor findings in children: prevalence, natural history, management, controversies, challenges, and dilemmas

Contact Info

Product

Resources

About